An Expert Panel Discussion on CAR T-Cell Therapy: The Value, Costs, and Strategies to Improve Access

An Expert Panel Discussion on CAR T-Cell Therapy: The Value, Costs, and Strategies to Improve Access

Moderator
Anthony J. Perissinotti, PharmD, BCOP
Hematology Clinical Pharmacist Specialist
Clinical Team Leader Hematology/Oncology
Adjunct Clinical Assistant Professor
University of Michigan – Michigan Medicine
Ann Arbor, Michigan

Faculty Presenters

Rebecca Borgert, PharmD, BCOP
Senior Director, Oncology Clinical Strategy and Innovation
Magellan Rx Management
Orlando, Florida

Zahra Mahmoudjafari, PharmD, BCOP, DPLA
Clinical Pharmacy Manager
The University of Kansas Health System
Kansas City, Kansas

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA
Director, Pharmacy Cancer Care
Assistant Professor of Pharmacy
Mayo Clinic
Rochester, Minnesota


Medical Writer

Jane de Lartigue, PhD
Medical Writer
Newberry, Florida
 
Program Description
A number of factors have contributed to the widespread use of chimeric antigen receptor-modified (CAR) T-cell therapy in the treatment of B-cell malignancies. However, increased utilization of CAR T-cell therapies comes with unique considerations for managed care professionals and requires pharmacists to collaborate with the multidisciplinary team to manage CAR T-cell–associated adverse effects. Despite the neurological toxicities, CAR T-cell therapies have shown significant improvement in cost-benefit compared with traditional chemotherapy. Potential economic benefits have spurred discussions about earlier initiation of CAR T-cell therapy in treatment algorithms, which could improve overall survival in patients with aggressive B-cell malignancies. To facilitate access to these treatments, managed care professionals and the healthcare team must work together to standardize processes for the integration of CAR T-cell therapies into clinical practice and determine optimal payment modalities to increase access for patients to improve outcomes. The panel members leading this discussion will address safety and cost considerations for the incorporation of CAR T-cell therapies into the treatment landscape of patients with B-cell malignancies.

Target Audience: Managed care and oncology pharmacists
Type of Activity: Application
Release date: April 26, 2021
Expiration date: April 26, 2022
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Interpret recent data for approved and emerging chimeric antigen receptor-modified (CAR) T-cell therapies and the impact of these treatments on the future paradigm of cancer care
• Analyze the costs of treatment as well as the value associated with CAR T-cell therapy
• Investigate strategies to improve management of costs and access to treatment associated with CAR T-cell therapy

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-163-H01-P. The activity is available for CE credit through April 26, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Faculty

Rebecca Borgert, PharmD, BCOP, has the following relevant financial relationship with a commercial interest to disclose:

• Consultant: Seagen

Zahra Mahmoudjafari, PharmD, BCOP, DPLA, has the following relevant financial relationships with commercial interests to disclose:

• Consultant: Celgene, Incyte, Novartis

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, has the following relevant financial relationships with commercial interests to disclose:

• Grant/Research Support: AstraZeneca, Janssen
• Consultant: AstraZeneca, G1 Therapeutics, Spectrum Pharmaceuticals, Sun Pharma
• Speakers Bureau: Pfizer

Anthony J. Perissinotti, PharmD, BCOP, has no relevant financial relationships with commercial interests to disclose.

Medical Writing Support

Jane de Lartigue, PhD, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy H. Seung, PharmD, BCOP, FHOPA; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms